Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Rhea-AI Summary

Innoviva (NASDAQ: INVA) reported strong Q2 2024 financial results, showcasing growth across multiple fronts. Key highlights include:

- GSK royalties of $67.2 million, up from $65.7 million in Q2 2023
- Net product sales of $21.7 million, a 38% year-over-year increase
- License revenue of $14.5 million, including an $8 million milestone payment for XACDURO® approval in China
- Net loss of $34.7 million, primarily due to unfavorable changes in investment fair values
- Completed $100 million share repurchase program

The company's core products, XACDURO® and XERAVA®, received recognition in important treatment guidelines. Innoviva remains focused on enhancing shareholder value through capital allocation and operational excellence.

Positive

• GSK royalties increased to $67.2 million in Q2 2024, up from $65.7 million in Q2 2023
• Net product sales grew 38% year-over-year to $21.7 million
• Received $14.5 million in license revenue, including an $8 million milestone payment for XACDURO® approval in China
• XACDURO® approved in China, expanding global footprint
• XACDURO® and XERAVA® recognized in important treatment guidelines, potentially boosting future sales
• Completed $100 million share repurchase program, enhancing shareholder value

Negative

• Reported net loss of $34.7 million in Q2 2024, compared to net income of $1.3 million in Q2 2023
• Unfavorable change in fair values of equity and long-term investments of $90.7 million, primarily due to lower share price of Armata Pharmaceuticals

Financial Analyst

Innoviva's Q2 2024 results demonstrate a mixed financial picture. On the positive side, the company's core royalty platform showed resilience, with GSK royalties increasing to $67.2 million from $65.7 million in Q2 2023. The IST portfolio exhibited strong growth, with net product sales rising 38% year-over-year to $21.7 million.

However, the company's bottom line was significantly impacted by a $90.7 million unfavorable change in fair values of equity and long-term investments, primarily due to Armata Pharmaceuticals' lower share price. This led to a net loss of $34.7 million or $0.55 per basic share, compared to a net income of $1.3 million in Q2 2023.

The company's cash position remains solid at $217.0 million, with an additional $94.0 million in receivables. Innoviva also completed its $100 million share repurchase program, which could be seen as a positive signal to investors about the company's confidence in its long-term prospects.

While the core business and IST portfolio show promise, the volatility in investment values poses a significant risk to Innoviva's financial stability. Investors should closely monitor the company's ability to manage its investment portfolio and continue growing its core operations to offset potential investment losses.

Medical Research Analyst

Innoviva's Q2 2024 results highlight significant progress in its specialty therapeutics portfolio. The standout performers were GIAPREZA®, XACDURO® and XERAVA®, collectively driving a 38% year-over-year increase in net product sales to $21.7 million.

Notably, XACDURO® achieved two major milestones: approval in China and recognition as the preferred agent for treating Carbapenem-resistant Acinetobacter baumannii infections in the 2024 IDSA treatment guidance. This positions XACDURO® favorably in the critical antibiotics market, especially given the World Health Organization's classification of Acinetobacter as a top-priority pathogen.

Similarly, XERAVA®'s inclusion in the 2024 SIS treatment guidelines for complicated intra-abdominal infections strengthens its market position. The recommendation to reserve XERAVA® for high-risk patients suggests its potential as a valuable last-line treatment option.

The progress of Zoliflodacin, a potential first-in-class treatment for uncomplicated gonorrhea, is also promising. With Phase 3 trials completed and NDA submission planned for early 2025, Innoviva could soon add another significant product to its portfolio.

These developments indicate Innoviva's growing influence in the antibiotics space, particularly in addressing critical and difficult-to-treat infections. However, investors should be aware that the path from clinical success to commercial viability can be challenging in the antibiotics market, often due to stewardship programs limiting the use of new antibiotics to prevent resistance.

Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million

Innoviva Specialty Therapeutics’ (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7 million

Important treatment guidelines and guidance updates recognized our key products: XACDURO^® by 2024 Infectious Diseases Society of America (IDSA); XERAVA^® by 2024 Surgical Infection Society

XACDURO^® approved in China

BURLINGAME, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2024, and highlighted select corporate achievements.

“Our robust second quarter continues to demonstrate the successful transformation of Innoviva. We have strong performance across multiple fronts, driven by our core GSK royalties portfolio and accelerating growth from our commercial products, GIAPREZA^®, XACDURO^® and XERAVA^®,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “We remain committed to enhancing shareholder value through thoughtful capital allocation and operational excellence. We also are excited about our portfolio of strategic healthcare assets, where we continue to see potential for significant value creation.”

Mr. Raifeld added, “In addition to driving strong operational delivery from our critical care and infectious disease platform IST, we continue to expand its global footprint and enhance recognition. Our partner in China, Zai Lab, successfully obtained regulatory approval for XACDURO^®, bringing us closer to making XACDURO^® available to all patients globally. In the U.S, important treatment guidelines and guidance updates recognized our key products, underscoring their life-saving potential. XACDURO^® was named the preferred agent for treatment of Carbapenem-resistant Acinetobacter baumannii infections in the 2024 Infectious Diseases Society of America (IDSA) treatment guidance. XERAVA^® is recommended by the 2024 Surgical Infection Society (SIS) treatment guidelines for empiric therapy in the management of complicated intra-abdominal infection.”

Financial Highlights

• Royalty revenue: Second quarter 2024 gross royalty revenue from Glaxo Group Limited (“GSK”) was $67.2 million, compared to $65.7 million for the second quarter 2023.
• Net Product Sales: Second quarter 2024 net product sales were $21.7 million, which included $13.1 million from GIAPREZA^®, $6.2 million from XERAVA^®, and $2.4 million from XACDURO^®, a 38% increase compared to $15.7 million for the second quarter 2023.
• License Revenue: Second quarter 2024 license revenue of $14.5 million included an $8 million milestone payment from our partner for the regulatory approval of XACDURO^® in China and $6.5 million in non-recurring cost-sharing reimbursements from our partner for product development.
• Equity and long-term investments: Second quarter 2024 net unfavorable change in fair values of equity and long-term investments of $90.7 million was primarily attributable to lower share price of Armata Pharmaceuticals (“Armata”), despite continued operational progress.
• Net income: The change in fair values of our investments negatively impacted second quarter 2024 earnings, resulting in a net loss of $34.7 million, or ($0.55) basic per share, compared to a net income of $1.3 million, or $0.02 basic per share, for the second quarter of 2023.
• Share repurchases: During the second quarter 2024, Innoviva completed its $100 million share repurchase program by repurchasing 0.4 million shares, for a total amount of approximately $5.3 million.
• Cash and cash equivalents: Totaled $217.0 million. Royalty and net product sales receivables totaled $94.0 million as of June 30, 2024.

Key Business and R&D Highlights

• XACDURO^® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use: targeted antibacterial for the treatment of patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii calcoaceticus complex.
  • In May 2024, XACDURO^® was approved in China by the National Medical Products Administration (NMPA) for use in Chinese patients 18 years of age and older.
  • In July 2024, XACDURO^® was named as the preferred agent for the treatment of Carbapenem-resistant Acinetobacter baumannii infections, in combination with a carbapenem, in the updated 2024 IDSA treatment guidance.
  • The World Health Organization considers Acinetobacter a top-priority pathogen worldwide that needs novel antibiotics¹.
• XERAVA^® (eravacycline), for injection is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms in patients 18 years or older.
  • In July 2024, XERAVA^® was named as a recommended agent for empiric therapy in the updated 2024 SIS treatment guidelines for the management of complicated intra-abdominal infections. SIS also recommended XERAVA^® be reserved for high-risk patients.
• Zoliflodacin: a potential first-in-class, single dose, oral antibiotic in development for the treatment of patients with uncomplicated gonorrhea is currently being developed in partnership with The Global Antibiotic Research & Development Partnership (GARDP).
  • Zoliflodacin has successfully completed Phase 3 clinical trials and the results were reported at ESCMID Global 2024. The Company expects to submit an NDA to the U.S. FDA in early 2025.

About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR^®/BREO^® ELLIPTA^® and ANORO^® ELLIPTA^®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO^® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA^® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA^® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.

ANORO^®, RELVAR^® and BREO^® are trademarks of the GSK group of companies.

Forward Looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR^®/BREO^® ELLIPTA^®, ANORO^® ELLIPTA^®, GIAPREZA^®, XERAVA^® and XACDURO^® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (“COVID-19”); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

References

(1) Tala, B., Jad, A., Claude, A., Jihad, I., Chantal, L., Rakan, N.,& Eid, A. (2017). Risk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia. Front. Cell. Infect. Microbiol., 04 May 2017, Sec. Molecular Bacterial Pathogenesis Volume 7 – 2017: https://doi.org/10.3389/fcimb.2017.00156

INNOVIVA, INC.
Condensed Consolidated Statements of Income and Comprehensive Income
(in thousands, except per share data)
(unaudited)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
			2024				2023				2024				2023
Revenue:
Royalty revenue, net (1)		$	63,742			$	62,265			$	122,157			$	119,123
Net product sales			21,651				15,727				40,735				27,241
License revenue			14,505				3,000				14,505				11,000
Total revenue			99,898				80,992				177,397				157,364
Expenses:
Cost of products sold (inclusive of amortization of inventory fair value adjustments)			8,472				8,979				19,443				17,728
Cost of license revenue			-				-				-				1,600
Selling, general and administrative			27,740				23,542				58,145				43,277
Research and development			2,560				14,989				6,438				27,577
Amortization of acquired intangible assets			6,440				4,958				12,880				8,763
Changes in fair values of equity method investments, net			60,108				19,911				24,766				4,094
Changes in fair values of equity and long-term investments, net			30,556				83				43,891				2,247
Interest and dividend income			(3,474	)			(3,553	)			(7,873	)			(6,918	)
Interest expense			5,802				4,382				11,653				8,809
Other expense, net			973				1,896				2,209				3,242
Total expenses, net			139,177				75,187				171,552				110,419
Income (loss) before income taxes			(39,279	)			5,805				5,845				46,945
Income tax expense (benefit), net			(4,594	)			4,525				3,998				10,800
Net income (loss) and comprehensive income (loss)		$	(34,685	)		$	1,280			$	1,847			$	36,145
Net income (loss) per share
Basic		$	(0.55	)		$	0.02			$	0.03			$	0.54
Diluted		$	(0.55	)		$	0.02			$	0.03			$	0.46
Shares used to compute net income (loss) per share
Basic			62,526				65,341				62,856				66,557
Diluted			62,526				65,489				63,064				88,175

(1) Total net revenue is comprised of the following (in thousands):
		Three Months Ended								Six Months Ended
		June 30,								June 30,
			2024				2023				2024				2023
		(unaudited)								(unaudited)
Royalties		$	67,198			$	65,721			$	129,069			$	126,035
Amortization of capitalized fees			(3,456	)			(3,456	)			(6,912	)			(6,912	)
Royalty revenue, net		$	63,742			$	62,265			$	122,157			$	119,123

INNOVIVA, INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
	June 30,			December 31,
	2024			2023
Assets
Cash and cash equivalents	$	217,003		$	193,513
Royalty and product sale receivables		93,980			84,075
Inventory		36,664			40,737
Prepaid expense and other current assets		10,630			25,894
Property and equipment, net		427			483
Equity and long-term investments		536,435			560,978
Capitalized fees paid, net		76,872			83,784
Right-of-use assets		3,118			2,536
Goodwill		17,905			17,905
Intangible assets		217,455			230,335
Deferred tax asset, net		11,446			-
Other assets		2,982			3,267
Total assets	$	1,224,917		$	1,243,507
Liabilities and stockholders’ equity
Other current liabilities	$	23,929		$	33,435
Accrued interest payable		3,422			3,422
Deferred revenue		855			1,277
Convertible senior notes, due 2025, net		191,659			191,295
Convertible senior notes, due 2028, net		255,623			254,939
Other long-term liabilities		72,065			71,870
Deferred tax liabilities, net		-			563
Income tax payable, long-term		11,849			11,751
Innoviva stockholders’ equity		665,515			674,955
Total liabilities and stockholders’ equity	$	1,224,917		$	1,243,507

INNOVIVA, INC.
Cash Flows Summary
(in thousands)
(unaudited)
	Six Months Ended
	June 30,
		2024				2023
Net cash provided by operating activities	$	80,765			$	63,866
Net cash used in investing activities		(43,038	)			(35,722	)
Net cash used in financing activities		(14,237	)			(146,168	)
Net change	$	23,490			$	(118,024	)
Cash and cash equivalents at beginning of period		193,513				291,049
Cash and cash equivalents at end of period	$	217,003			$	173,025

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731216589/en/

Innoviva, Inc.

David Patti

Corporate Communications

(908) 421-5971

david.patti@inva.com

Investors and Media:

Argot Partners

(212) 600-1902

innoviva@argotpartners.com

Source: Innoviva, Inc.

FAQ

What were Innoviva's (INVA) Q2 2024 royalty revenues from GSK?

Innoviva's Q2 2024 gross royalty revenue from GSK was $67.2 million, compared to $65.7 million for Q2 2023.

How much did Innoviva's (INVA) net product sales grow in Q2 2024?

Innoviva's net product sales grew 38% year-over-year to $21.7 million in Q2 2024.

What was Innoviva's (INVA) net income/loss for Q2 2024?

Innoviva reported a net loss of $34.7 million, or ($0.55) per basic share, for Q2 2024.

Did Innoviva (INVA) receive any milestone payments in Q2 2024?

Yes, Innoviva received an $8 million milestone payment for the regulatory approval of XACDURO® in China.

What recent developments occurred for Innoviva's (INVA) products XACDURO® and XERAVA®?

XACDURO® was approved in China and named as the preferred agent for certain infections in the 2024 IDSA treatment guidance. XERAVA® was recommended in the 2024 SIS treatment guidelines for complicated intra-abdominal infections.